The Ratutrelvir Phase 2 news is the real catalyst here, and the stock is finally waking up to it. 🧪 After a period of consolidation, we're seeing a bullish WMA crossover and the RSI just broke from the "meh" 40s into a healthier 50s trend. Volume confirms the move isn't a fluke. This looks like the start of a real leg up. BUY. #AntiviralAction

Whoa, Traws is buzzing! A fresh $72M war chest and Phase 2 COVID data due *this year*? That's rocket fuel. 🚀 The stock's been on a tear, and the RSI hovering in the 70s confirms it's hot. The 9-day EMA is pulling ahead of the 21-day, a classic bullish signal. It's a bit overbought, but with news this potent, pullbacks are likely buys. This momentum has legs. #BUY the buzz. ☕

Hot take on TRAW: This bird flu/COVID buzz is legit! 🐦🔥 The stock's been on a heater, but the RSI cooling from 73 to 66 tells me the initial frenzy is settling into a real uptrend. With phase 2 data due *this year* and that monster volume on Sept 9th, smart money is positioning for news. The 9-day EMA is pulling ahead of the 21-day—bullish signal. This is a BUY on any dip. #PandemicPortfolio